AAMU
FENC icon

Amundi Asset Management US’s Fennec Pharmaceuticals FENC Stock Holding History

Amundi Asset Management US’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,800
Closed -$56K – 1616
2018
Q3 		$56K Buy
+6,800
New +$63.1K ﹤0.01% 1559

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Amundi Asset Management US's FENC Position: Q4 2018 in Review

Amundi Asset Management US sold out of Fennec Pharmaceuticals (FENC) in Q4 2018, closing a stake of 6,800 shares — an estimated $56K sold.

Amundi Asset Management US first reported a position in FENC in Q3 2018 and held it in 1 quarter. The position peaked at $56K in Q3 2018. 47 funds tracked by Wall St. Rank hold FENC as of Q4 2018.

  • Amundi Asset Management US reported no remaining Fennec Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 6,800 Fennec Pharmaceuticals shares in Q4 2018, an estimated $56K.
  • Amundi Asset Management US first reported a position in Fennec Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Amundi Asset Management US's Fennec Pharmaceuticals position peaked at $56K in Q3 2018.
  • 47 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.